Pharmacogenomics and personalized medicine in neuropsychiatry.
about
The epigenome, 4D nucleome and next-generation neuropsychiatric pharmacogenomicsDifferent Paths to Core Pathology: The Equifinal Model of the Schizophrenia SyndromeGlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric DisordersA Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia.Moving psychopharmacological drug development to the developing world.The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism.Role of the axonal initial segment in psychiatric disorders: function, dysfunction, and interventionAn HDAC-dependent epigenetic mechanism that enhances the efficacy of the antidepressant drug fluoxetine.Prediction of treatment outcomes in psychiatry--where do we stand ?Catehol-o-methyltransferase gene Val158met polymorphism as a potential predictor of response to computer-assisted delivery of cognitive-behavioral therapy among cocaine-dependent individuals: Preliminary findings from a randomized controlled trialGenetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.Can adaptive treatment improve outcomes in family-based therapy for adolescents with anorexia nervosa? Feasibility and treatment effects of a multi-site treatment studyLeveraging genomic data in smoking cessation trials in the era of Precision Medicine: Why and how.Genetic modulation of oxytocin sensitivity: a pharmacogenetic approachPatient heal thyself: modeling and treating neurological disorders using patient-derived stem cells.Epigenetic and pharmacological regulation of 5HT3 receptors controls compulsive ethanol seeking in miceWhat is the role of pharmacogenetics in clinical psychiatry?New considerations for hiPSC-based models of neuropsychiatric disorders.Depressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder
P2860
Q26785674-D17824B7-424F-40B3-B81B-E37300AC68F0Q30357827-558AA1BA-7E5A-4F3A-8772-248FEFF156F3Q30756194-E666E2F6-DADF-44F1-9C9F-7CB582B5D2EAQ33624417-6B5F64C2-ED59-4F90-BC98-E7A2D83A937EQ33692055-99CE9A1D-34DD-426C-9346-966584BE5A76Q33764400-D488D788-CC6D-44EC-ADF0-6ABD78C058B9Q34071914-069D66A2-65BE-45C6-98E1-18C0E535DFF3Q35035549-38B42987-5B1E-46AA-B4A7-502964E7F759Q35109159-47F98C99-3E0D-4CCA-8F26-E6B4FFB63F73Q35893529-9B56499C-A6FA-4920-A97F-038E73C68B45Q35956179-D9C84510-4C2C-412E-8E93-98A611C1892AQ36068895-FD9985F9-3E02-4B42-832E-A2BF80A32871Q36370325-E922DC48-1D83-42A3-BD1A-B02DA767D346Q37058657-944885FF-4B8D-4554-BC8B-F9AD721587A8Q37199722-B47C1C4E-0E7A-4C5D-970C-CC61E8D0D201Q37732986-67224059-0A9C-48CB-B3B8-F6D12AF1942BQ50734208-7440E8D4-0C43-4FEF-9A62-772626154AA5Q52372478-9FD83CC5-2938-48ED-B226-93032C5725FAQ57703141-7E5BCB44-CBC9-4B02-ADD9-ACD585DBA850
P2860
Pharmacogenomics and personalized medicine in neuropsychiatry.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Pharmacogenomics and personalized medicine in neuropsychiatry.
@ast
Pharmacogenomics and personalized medicine in neuropsychiatry.
@en
Pharmacogenomics and personalized medicine in neuropsychiatry.
@nl
type
label
Pharmacogenomics and personalized medicine in neuropsychiatry.
@ast
Pharmacogenomics and personalized medicine in neuropsychiatry.
@en
Pharmacogenomics and personalized medicine in neuropsychiatry.
@nl
prefLabel
Pharmacogenomics and personalized medicine in neuropsychiatry.
@ast
Pharmacogenomics and personalized medicine in neuropsychiatry.
@en
Pharmacogenomics and personalized medicine in neuropsychiatry.
@nl
P2860
P1433
P1476
Pharmacogenomics and personalized medicine in neuropsychiatry.
@en
P2093
Thomas R Insel
P2860
P304
P356
10.1016/J.NEURON.2012.05.004
P407
P577
2012-06-01T00:00:00Z